Colony-forming unit-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation.
暂无分享,去创建一个
R. Sothern | O. Laerum | R. Smaaland | K. Lote | O. Sletvold | R. Bjerknes | RB Sothern | Robert Bjerknes | Ole Didrik Laerum | Knut Lote
[1] Richard J. Jones. Autologous bone marrow transplantation , 1993, Current opinion in oncology.
[2] O D Laerum,et al. DNA synthesis in human bone marrow is circadian stage dependent. , 1991, Blood.
[3] R Simon,et al. Selecting drug combinations based on total equivalent dose (dose intensity) , 1990, Journal of the National Cancer Institute.
[4] D. Kerr,et al. The myelotoxicity of carboplatin is influenced by the time of its administration , 1990, Hematological oncology.
[5] R. Wittes,et al. Autologous bone marrow transplantation. Current status and future directions. , 1989, Annals of internal medicine.
[6] Recombinant GM-CSF in myelosuppression of chemotherapy. , 1989, The New England journal of medicine.
[7] P. Ludman,et al. DOES STRESSFUL VENEPUNCTURE EXPLAIN INCREASED MIDNIGHT SERUM CORTISOL CONCENTRATION? , 1988, The Lancet.
[8] A. Reinberg,et al. Circadian time dependence of murine tolerance for carboplatin. , 1988, Toxicology and applied pharmacology.
[9] A. Nienhuis. Hematopoietic growth factors: biologic complexity and clinical promise. , 1988, The New England journal of medicine.
[10] W. Hryniuk,et al. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. , 1987, Seminars in oncology.
[11] R. Klevecz,et al. Circadian gating of S phase in human ovarian cancer. , 1987, Cancer research.
[12] V. Devita. Dose-response is alive and well. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Hrushesky. Circadian timing of cancer chemotherapy. , 1985, Science.
[14] W. Hryniuk,et al. The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] F. Lévi,et al. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. , 1982, Cancer research.
[16] Priv.-Doz. Dr. Hans-Peter Lohrmann,et al. Recent Results in Cancer Research , 2011 .
[17] E. Frei,et al. Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.
[18] G. Spitzer,et al. Diurnal changes in circulating myeloid progenitor cells in man , 1980, American journal of hematology.
[19] S. Akman,et al. Diurnal variation of circulating human myeloid progenitor cells. , 1980, Experimental hematology.
[20] B. Barlogie,et al. Flow cytometry of DNA content in human bone marrow: a critical reappraisal. , 1980, Blood.
[21] T. Schlunk,et al. The influence of culture conditions on the production of colony-stimulating activity by human placenta. , 1980, Experimental Hematology.
[22] F Halberg,et al. Methods for cosinor-rhythmometry. , 1979, Chronobiologia.
[23] A. Burgess,et al. Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells. , 1977, Blood.
[24] F. Halberg,et al. Close reproduction by different laboratories of characteristics of circadian rhythm in 1-beta-D-arabinofuranosylcytosine tolerance by mice. , 1976, Cancer research.
[25] F. Halberg,et al. Increased Tolerance of Leukemic Mice to Arabinosyl Cytosine with Schedule Adjusted to Circadian System , 1972, Science.
[26] A. Mauer,et al. DIURNAL VARIATION OF PROLIFERATIVE ACTIVITY IN THE HUMAN BONE MARROW. , 1965, Blood.
[27] E. Cronkite,et al. Mitotic indices of human bone marrow cells. I. Number and cytologic distribution of mitoses. , 1962, Blood.
[28] D. Buttenberg,et al. [Chemotherapy of advanced ovarian cancer]. , 1960, Die Medizinische Welt.